Capricor Therapeutics has submitted results from an open-label extension of its failed Phase 3 study of deramiocel — a cell therapy candidate for Duchenne muscular dystrophy — to the U.S. Food and Drug Administration. The company is taking this step after the Phase 3 program did not meet expectations, according to the reporting in STAT. The public filing of extension data appears intended to influence the FDA review that is now anticipated to result in non-approval.
The source states that Capricor remains outwardly confident in the prospects of deramiocel, even while the Phase 3 outcome was characterized as unsuccessful. The article reports the submission of extension data as the company’s current strategy to engage the regulator following the pivotal trial failure.
The STAT report frames the submission of open-label-extension results as a stall tactic. In that characterization, the company’s filing is portrayed primarily as an attempt to delay or alter an imminent negative regulatory action rather than as a definitive remedy to the deficiencies that led to the Phase 3 failure.
The reporting explicitly states that submitting these extension data is not a substantive alternative to the type of evidence typically required to support approval after a failed randomized Phase 3 trial. The implication in the article is that open-label-extension data — with inherent limitations such as lack of randomization and potential bias — are unlikely to satisfy the evidentiary standards for approval on their own.
According to the STAT piece, the only remaining credible path for Capricor to secure approval of deramiocel would be to design and conduct an entirely new, randomized clinical trial. The article indicates that open-label-extension results cannot replace the level of evidence provided by a well-designed randomized controlled trial in the regulatory assessment for a failed Phase 3 program.
The reporting does not include details on what a new trial would entail (such as sample size, endpoints, or duration), nor does it provide any timeline for when such a trial might begin or conclude. The author’s assessment is categorical in stating that a new randomized trial is the only remaining option reported in the source.
Publicly, Capricor has maintained confidence in deramiocel even as it submitted the open-label-extension data to the FDA. The STAT article notes this public posture but also highlights that it is not clear from available information why the company retains that confidence.
Key specifics are not reported in the source: the article does not provide the actual extension-study results, any statistical summaries, detailed safety data, or excerpts of FDA communications. The source does not report whether the FDA has formally responded to the new submission or issued a timeline for a decision based on the extension data.
The STAT article is a subscriber-only (STAT+) exclusive, and the publicly available summary is limited. As reported, the piece does not include granular trial data, full regulatory correspondence, or explicit statements from independent experts evaluating the extension data. Consequently, the factual record available in the source is narrowly focused on the company’s submission and the author’s interpretation that it functions as a temporary delay tactic.
Because these details are not provided in the source, readers cannot assess from this article alone the strength or weakness of the extension results, nor can they know whether there are plausible scientific arguments that the FDA might find persuasive without a new randomized trial.
The key points the source reports are straightforward: Capricor has pursued an unusual regulatory move after a failed Phase 3, and the author views the filing as unlikely to avert a near-certain rejection unless Capricor conducts a new randomized trial. The company’s public confidence contrasts with the author’s skeptical reading of the regulatory prospects.
The article is presented as an exclusive by Adam Feuerstein in the STAT+ newsletter series; fuller details and analysis are available behind STAT’s subscriber paywall, and the public summary leaves several important data and regulatory questions unanswered.
(Details such as numerical trial outcomes, FDA correspondence, or independent expert assessments were not reported in the source.)